查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1919317

聚合物心臟瓣膜市场：按产品类型、材质、应用和最终用户划分 - 全球预测（2026-2032年）

Polymer Heart Valves Market by Product Type, Material Composition, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年聚合物心臟瓣膜市场价值为4.1927亿美元，预计到2026年将成长至4.5087亿美元，年复合成长率为5.35%，到2032年将达到6.0394亿美元。

关键市场统计数据
基准年 2025 4.1927亿美元
预计年份：2026年 4.5087亿美元
预测年份 2032 6.0394亿美元
复合年增长率 (%) 5.35%

本文简要概述了影响聚合物心臟瓣膜创新和相关人员优先事项的当代临床、监管和商业性趋势。

聚合物心臟瓣膜领域融合了先进材料科学、微创心臟病学以及日益复杂的监管体系。本执行摘要总结了影响聚合物瓣膜器械临床应用、生产策略和商业性定位的核心进展。其旨在为需要了解当前趋势及其对未来决策的实际影响的高阶主管、临床负责人和策略投资者提供简洁而又全面的资讯。

本文对正在重新定义聚合物阀门开发竞争优势的技术、程序、监管和供应链转折点进行了分析概述。

近年来，聚合物心臟瓣膜的评估方式发生了多项变革性变化。材料创新已超越了渐进式改进，新一代聚合物的研发旨在提高抗疲劳性、降低钙化风险并实现更薄的瓣叶厚度。因此，先前仍处于临床前阶段的器械概念正逐步进入临床评估阶段，迫使相关人员和支付方重新评估其与外科组织瓣膜和机械瓣膜相比的价值提案。

重点分析累积关税环境对聚合物心臟瓣膜价值链的筹资策略、生产韧性与资本配置决策的影响

2025年实施的关税对聚合物心臟瓣膜生态系统产生了累积影响，重塑了成本结构和供应商选择标准。由于关税改变了进口聚合物基材和精密零件的相对竞争力，拥有全球供应链的製造商面临投入要素波动性增加的问题。为应对这项挑战，一些公司加快了近岸外包的步伐，以稳定利润率并缩短物流前置作业时间；而另一些公司则透过谈判长期合约和实现供应商多元化，来保护生产免受关税暂时波动的影响。

深入的细分洞察揭示了产品类型、临床应用、终端用户环境和细微的材料成分如何共同影响设计检验和商业化路径。

细分市场的细微差别会影响产品设计、临床定位和客户参与方面的实际选择。按产品类型划分，市场涵盖外科手术和经导管介入两种选择。外科手术策略进一步分为微创手术和开胸手术，而经导管介入方法则分为球囊扩张型和自扩张式输送系统。设计人员必须将瓣叶材料特性与展开机制和预期的血流动力学负荷相匹配，并根据所选的输送方式调整瓣叶厚度和支架相互作用。

区域趋势和采纳路径表明，法规结构、报销机制和临床能力如何驱动世界不同地区差异化的市场进入策略。

区域趋势影响监管策略、报销方式和技术推广速度，主要可分为三大区域：美洲、欧洲、中东和非洲以及亚太地区。在美洲，一体化的支付体系和集中的先进心臟病计画为差异化技术的早期应用创造了有利环境，前提是开发商能够提供令人信服的临床证据和清晰的编码路径。同时，供应链因素和关税风险正促使製造商考虑在该地区进行在地化生产，以保持成本竞争力并加快交付速度。

战略竞争情报概述了专有材料、生产规模和临床合作如何为聚合物阀门开发商创造永续的差异化优势。

聚合物阀门领域的竞争格局呈现出垂直整合製造商、专业组件供应商和临床合作者并存的局面。拥有专有聚合物配方或关键涂层或加工技术的公司能够显着提高市场进入门槛，尤其是在这些优势与可靠的临床前检验和清晰的生产规模化路径相结合的情况下。器材开发商与材料科学公司之间的策略联盟，透过智慧财产权共用和共同开发契约，能够实现快速原型製作和迭代测试，从而加快部分专案的临床应用进程。

为将材料创新、供应链韧性和证据生成转化为切实可行的商业和临床实施计划，提出跨部门的可操作建议

优先考虑材料层面的差异化，使聚合物化学性质与预期的给药方式和解剖应用相符。设计、工程和临床团队的早期协作可缩短迭代周期并加快检验里程碑的达成。这种整合方法可同时优化瓣膜动态、框架相互作用和灭菌途径。

我们以透明的方式解释我们的混合方法，该方法结合了初步访谈、系统的二次分析和严格的资料三角验证，以确保可信度。

本研究整合了多种资讯来源和方法，对聚合物心臟瓣膜的现状进行了透明且可重复的评估。主要研究包括对临床医生、企业采购人员、监管专家和材料科学家进行结构化访谈，以了解操作实践、临床偏好和市场进入的考量。访谈通讯协定采用统一的问题格式，以便对相关人员进行比较和进行主题分析。

摘要重点阐述了将材料和製程创新转化为持续的临床和商业性优势的策略要务。

聚合物心臟瓣膜代表着材料工程、製程创新和不断变化的监管要求三者交汇的策略转折点。能够将聚合物科学与切实可行的临床路径、稳健的生产策略和系统的证据生成相结合的机构，将抓住最具前景的机会。在这些领域取得卓越的执行力，将决定技术优势能否转化为持续的临床应用和永续的经营模式。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的聚合物心臟瓣膜市场

  • 外科
    • 微创
    • 开胸手术
  • 经导管
    • 球囊扩张型
    • 自膨胀

9. 依材料成分分類的聚合物心臟瓣膜市场

  • 聚对苯二甲酸乙二酯
  • 聚氨酯脲
    • 医用级聚氨酯
    • 热塑性聚氨酯
  • 硅氧烷
    • 高强度硅胶
    • 医用级硅胶

第十章 按应用分類的聚合物心臟瓣膜市场

  • 主动脉瓣
  • 二尖瓣
  • 肺动脉瓣
  • 三尖瓣

第十一章 按最终用户分類的聚合物心臟瓣膜市场

  • 门诊手术中心
  • 医院
    • 心臟专科医院
    • 三级医院
  • 专科诊所

12. 各地区聚合物心臟瓣膜市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按组别分類的聚合物心臟瓣膜市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国聚合物心臟瓣膜市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国聚合物心臟瓣膜市场

第十六章：中国聚合物心臟瓣膜市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3F Therapeutics AG
  • Abbott Laboratories
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • CryoLife, Inc.
  • DirectFlow Medical, Inc.
  • Edwards Lifesciences Corporation
  • JenaValve Technology, Inc.
  • LivaNova PLC
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • Terumo Corporation
  • ValveMed Inc.
  • ValveXchange, Inc.
Product Code: MRR-F14BA1B341AE

The Polymer Heart Valves Market was valued at USD 419.27 million in 2025 and is projected to grow to USD 450.87 million in 2026, with a CAGR of 5.35%, reaching USD 603.94 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 419.27 million
Estimated Year [2026] USD 450.87 million
Forecast Year [2032] USD 603.94 million
CAGR (%) 5.35%

A concise high-level introduction that frames the contemporary clinical, regulatory, and commercial dynamics shaping polymer valve innovation and stakeholder priorities

The polymer heart valve sector sits at the intersection of advanced materials science, minimally invasive cardiology, and increasingly complex regulatory pathways. This executive summary synthesizes core developments shaping clinical adoption, manufacturing strategies, and commercial positioning for polymer-based valvular devices. It is written to inform senior executives, clinical leaders, and strategic investors who require a concise yet comprehensive view of current dynamics and practical implications for near-term decision making.

Across clinical settings, device developers are navigating a rapidly evolving evidence base that emphasizes durability, hemodynamic performance, and biocompatibility. At the same time, suppliers are confronting supply chain constraints, evolving reimbursement frameworks, and heightened scrutiny from regulators regarding long-term outcomes. These converging forces are accelerating strategic prioritization around material selection, delivery mode innovation, and post-market surveillance design. The subsequent sections translate these signals into actionable insights and operational recommendations that support product development, market entry, and portfolio management.

An analytical overview of the pivotal technological, procedural, regulatory, and supply chain shifts that are redefining competitive advantage in polymer valve development

Recent years have produced several transformative shifts that are recalibrating how stakeholders evaluate polymer heart valves. Material innovation has progressed beyond incremental improvements, with next-generation polymers designed to enhance fatigue resistance, reduce calcification potential, and enable thinner leaflet profiles. Consequently, device concepts that were once confined to preclinical demonstration are moving into clinical evaluation, prompting clinicians and payers to reassess comparative value propositions relative to surgical tissue and mechanical alternatives.

Concurrently, the procedural landscape is changing as transcatheter approaches expand anatomical reach and patient eligibility. Enhanced delivery systems and imaging integration have increased confidence among interventional teams, supporting broader adoption in centers with established structural heart programs. Supply chain restructuring constitutes another major shift; manufacturers are balancing global supplier networks with localized production strategies to mitigate trade disruptions and strengthen quality oversight. Regulatory authorities are also adapting, placing renewed emphasis on long-term real-world evidence and lifecycle management. Taken together, these shifts create both opportunity and executional complexity, underscoring the need for coordinated clinical, regulatory, and commercial strategies to realize durable patient and business outcomes.

A focused analysis of how the cumulative tariff landscape has influenced procurement strategies, production resilience, and capital allocation decisions across the polymer heart valve value chain

Tariff actions introduced in 2025 have exerted a cumulative effect on the polymer heart valve ecosystem by reshaping cost structures and supplier selection criteria. Manufacturers with globalized supply chains experienced increased input variability as duties altered the relative competitiveness of imported polymer substrates and precision components. In response, several firms accelerated nearshoring initiatives to stabilize margins and shorten logistics lead times, while others negotiated longer-term contracts or diversified supplier portfolios to shield production from episodic tariff volatility.

Beyond procurement, tariffs influenced capital allocation decisions. Investment in redundant production lines and intensified quality audits became a pragmatic response to mitigate interruption risk. Clinical trial management also felt indirect impacts, as device sponsors adjusted site budgets to account for higher import costs of specialty materials and tooling. Procurement teams and finance leaders have therefore prioritized scenario planning and tariff sensitivity analyses to preserve program timelines. Collectively, these developments have made resilience and flexibility central to commercial planning, encouraging cross-functional investments that balance cost containment with the need to maintain product integrity and regulatory compliance.

Deep segmentation insights that reveal how product type, clinical application, end user settings, and nuanced material compositions collectively shape design validation and commercial pathways

Segmentation nuance drives practical choices across product design, clinical positioning, and customer engagement. When differentiated by product type, the market encompasses Surgical approaches and Transcatheter options, with Surgical strategies further categorized into Minimally Invasive and Open Heart techniques while Transcatheter approaches distinguish between Balloon Expandable and Self Expandable delivery systems. Designers must therefore reconcile leaflet material properties with deployment mechanics and expected hemodynamic loading, tailoring leaflet thickness and frame interaction to the selected delivery modality.

Application-based segmentation into Aortic, Mitral, Pulmonary, and Tricuspid anatomies imposes distinct anatomical constraints and durability expectations. Each valve position presents unique calcification patterns, annular dynamics, and exposure to varying pressure regimes, which in turn influence preclinical test protocols and patient selection criteria. End user segmentation between Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, with Hospitals further differentiated into Cardiac Specialty Hospitals and Tertiary Care Hospitals, informs distribution, training, and support models. High-volume cardiac centers will prioritize integrated training and on-site technical support, whereas ambulatory settings emphasize streamlined logistics and predictable procedure times.

Material composition choices-spanning Polyethylene Terephthalate, Polyurethane Urea, and Siloxane-are at the core of performance and regulatory pathways. Polyurethane Urea is further understood through distinctions between Medical Grade PU and Thermoplastic PU, each offering different processing characteristics and fatigue profiles. Siloxane formulations are evaluated across High Strength Silicone and Medical Grade Silicone variants, with trade-offs between tensile properties and biostability. These material distinctions compel a systems-level approach to design verification, sterilization validation, and clinical data generation, ensuring that product positioning aligns with both procedural use cases and end-user expectations.

Regional dynamics and adoption pathways that map how regulatory frameworks, reimbursement mechanisms, and clinical capacity drive differentiated market access strategies across global geographies

Regional dynamics influence regulatory strategy, reimbursement approaches, and adoption velocity across three broad geographies: Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidated payer systems and a concentration of advanced cardiac programs create fertile ground for early adoption of differentiated technologies, provided developers present compelling clinical evidence and clear coding pathways. Conversely, supply chain considerations and tariff exposure have prompted manufacturers to evaluate localized production for this region to maintain cost competitiveness and shorten delivery cycles.

The Europe, Middle East & Africa region features heterogeneous regulatory regimes and reimbursement mechanisms, requiring tailored market access strategies. Centralized regulatory pathways in some European jurisdictions favor coordinated clinical dossiers and shared real-world evidence initiatives, while other markets within the region may prioritize cost-effectiveness demonstrations. In the Asia-Pacific context, rapid demographic shifts and expanding interventional cardiology capacity have increased demand, yet market entry strategies must account for local regulatory nuances, partner selection, and culturally specific adoption drivers. Across all regions, collaboration with leading clinical centers and phased evidence generation remain essential to translate technical differentiation into durable clinical and commercial outcomes.

Strategic competitive intelligence outlining how proprietary materials, manufacturing scale, and clinical partnerships create sustainable differentiation for polymer valve developers

Competitive dynamics in the polymer valve arena are characterized by a mix of vertically integrated manufacturers, specialized component suppliers, and clinical collaborators. Companies that secure proprietary polymer formulations or that control critical coating and processing technologies enjoy meaningful barriers to entry, especially when those assets are paired with robust preclinical validation and clear manufacturing scale-up pathways. Strategic partnerships between device developers and material science firms have accelerated time-to-clinic for some programs, as shared IP and co-development agreements enable rapid prototyping and iterative testing.

Market leaders are also distinguishing themselves through investments in quality systems, modular manufacturing footprints, and post-market evidence platforms. Firms that align clinical development with comprehensive post-market surveillance strategies are better positioned to respond to regulatory queries and to communicate long-term safety narratives to clinicians and payers. In addition, alliance activity-ranging from distribution agreements to targeted acquisitions of niche suppliers-reflects a broader push to control supply chain inputs and to offer bundled solutions that simplify adoption for hospital systems and specialty centers. These strategic moves are shaping a competitive landscape where technical differentiation must be supported by operational excellence and stakeholder trust.

Actionable, cross-functional recommendations that translate material innovation, supply resilience, and evidence generation into pragmatic commercial and clinical execution plans

Prioritize material-level differentiation that aligns polymer chemistry with the intended delivery modality and anatomical application. Early alignment between design, engineering, and clinical teams reduces iteration cycles and accelerates validation milestones. This integrated approach ensures that leaflet mechanics, frame interactions, and sterilization pathways are concurrently optimized.

Invest in flexible manufacturing capacity and quality systems that support both rapid scale-up and localization. Modular production cells and dual-sourcing strategies mitigate trade-related disruptions and enable responsive supply to diverse regional markets. Coupling these investments with robust supplier qualification practices minimizes operational risk.

Embed real-world evidence planning into the earliest clinical development stages. Define endpoints and registry partnerships that capture durability, reintervention rates, and quality-of-life measures relevant to payers and clinicians. A transparent evidence generation plan strengthens reimbursement discussions and post-market confidence.

Forge targeted clinical and commercial partnerships with centers of excellence and regional distributors to streamline training, proctoring, and launch execution. Tailored support models for ambulatory centers versus tertiary hospitals will increase procedure throughput and device adoption.

Adopt proactive regulatory engagement and lifecycle management strategies that anticipate post-market data expectations. Early dialogues with regulators can clarify acceptable evidence pathways and post-approval commitments, reducing downstream uncertainty.

Allocate resources to customer education and value communication that translate biophysical advantages into tangible clinical benefits. Case-based learning, simulation training, and peer-led outcomes dissemination build clinician confidence and drive referral patterns.

Monitor geopolitical and tariff trends continuously and develop scenario-based financial plans that preserve program agility. Engage cross-functional teams to reassess supplier terms and to model the operational implications of trade policy shifts.

Leverage strategic M&A selectively to acquire specialized polymer technologies, processing capabilities, or clinical infrastructure that complement existing portfolios. Integration should prioritize maintaining development velocity and protecting critical know-how.

A transparent description of the mixed-methods research approach that integrates primary interviews, systematic secondary analysis, and rigorous data triangulation to ensure reliability

This research synthesizes multiple sources and methods to produce a transparent, reproducible assessment of the polymer heart valve landscape. Primary research included structured interviews with clinicians, enterprise procurement leaders, regulatory experts, and materials scientists to capture operational realities, clinical preferences, and market access considerations. Interview protocols emphasized consistent questioning to enable cross-stakeholder comparison and thematic analysis.

Secondary research comprised systematic reviews of peer-reviewed clinical literature, regulatory guidance documents, and engineering test standards to map technical performance criteria and approval pathways. Supplier mapping and patent landscaping were performed to identify concentration risks and proprietary material advantages. Data triangulation was used throughout to reconcile divergent perspectives, and key findings were validated through follow-up interviews and cross-referencing with publicly available regulatory filings.

The methodology acknowledges limitations inherent in emerging technology assessment, including evolving clinical evidence and variable reporting standards. To mitigate these constraints, the study adopted conservative evidence weighting, highlighted areas of uncertainty, and recommended continuous monitoring of post-market registries and regulatory updates. Ethical safeguards and confidentiality protocols governed all primary engagements, ensuring candid stakeholder insights while protecting proprietary information.

A concluding synthesis that underscores the strategic imperatives for converting material and procedural innovation into durable clinical and commercial advantage

Polymer heart valves represent a strategic inflection point where materials engineering meets procedural innovation and evolving regulatory expectations. The most promising opportunities will be realized by organizations that integrate polymer science with pragmatic clinical pathways, robust manufacturing strategies, and disciplined evidence generation. Execution excellence across these domains will determine whether technological advantages translate into durable clinical adoption and sustainable business models.

Looking ahead, stakeholders should expect continued emphasis on long-term outcomes, device lifecycle transparency, and operational resilience. Developers who proactively address these imperatives-through collaborative clinical programs, flexible supply strategies, and clear communication of value-will enhance their ability to navigate competitive pressures and policy uncertainties. Ultimately, the pathway to success combines technical differentiation with disciplined commercialization and stakeholder-centric evidence frameworks.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Polymer Heart Valves Market, by Product Type

  • 8.1. Surgical
    • 8.1.1. Minimally Invasive
    • 8.1.2. Open Heart
  • 8.2. Transcatheter
    • 8.2.1. Balloon Expandable
    • 8.2.2. Self Expandable

9. Polymer Heart Valves Market, by Material Composition

  • 9.1. Polyethylene Terephthalate
  • 9.2. Polyurethane Urea
    • 9.2.1. Medical Grade Pu
    • 9.2.2. Thermoplastic Pu
  • 9.3. Siloxane
    • 9.3.1. High Strength Silicone
    • 9.3.2. Medical Grade Silicone

10. Polymer Heart Valves Market, by Application

  • 10.1. Aortic
  • 10.2. Mitral
  • 10.3. Pulmonary
  • 10.4. Tricuspid

11. Polymer Heart Valves Market, by End User

  • 11.1. Ambulatory Surgical Center
  • 11.2. Hospitals
    • 11.2.1. Cardiac Specialty Hospitals
    • 11.2.2. Tertiary Care Hospitals
  • 11.3. Specialty Clinics

12. Polymer Heart Valves Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Polymer Heart Valves Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Polymer Heart Valves Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Polymer Heart Valves Market

16. China Polymer Heart Valves Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3F Therapeutics AG
  • 17.6. Abbott Laboratories
  • 17.7. Biotronik SE & Co. KG
  • 17.8. Boston Scientific Corporation
  • 17.9. CryoLife, Inc.
  • 17.10. DirectFlow Medical, Inc.
  • 17.11. Edwards Lifesciences Corporation
  • 17.12. JenaValve Technology, Inc.
  • 17.13. LivaNova PLC
  • 17.14. Medtronic plc
  • 17.15. Meril Life Sciences Pvt. Ltd.
  • 17.16. Terumo Corporation
  • 17.17. ValveMed Inc.
  • 17.18. ValveXchange, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POLYMER HEART VALVES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POLYMER HEART VALVES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY OPEN HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY OPEN HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY OPEN HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY BALLOON EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY BALLOON EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY BALLOON EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SELF EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SELF EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SELF EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE PU, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE PU, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE PU, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY THERMOPLASTIC PU, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY THERMOPLASTIC PU, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY THERMOPLASTIC PU, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HIGH STRENGTH SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HIGH STRENGTH SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HIGH STRENGTH SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MEDICAL GRADE SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MITRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MITRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY MITRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY PULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRICUSPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRICUSPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TRICUSPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY CARDIAC SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY CARDIAC SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY CARDIAC SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 172. GCC POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 173. GCC POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 174. GCC POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 175. GCC POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 199. G7 POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 202. G7 POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 203. G7 POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 205. G7 POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. G7 POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. G7 POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 212. NATO POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 213. NATO POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 215. NATO POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. NATO POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL POLYMER HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA POLYMER HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA POLYMER HEART VALVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA POLYMER HEART VALVES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA POLYMER HEART VALVES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA POLYMER HEART VALVES MARKET SIZE, BY MATERIAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA POLYMER HEART VALVES MARKET SIZE, BY POLYURETHANE UREA, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA POLYMER HEART VALVES MARKET SIZE, BY SILOXANE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA POLYMER HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA POLYMER HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA POLYMER HEART VALVES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)